GENPREX (GNPX)
(Delayed Data from NSDQ)
$2.25 USD
+0.23 (11.39%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $2.29 +0.04 (1.78%) 6:50 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.25 USD
+0.23 (11.39%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $2.29 +0.04 (1.78%) 6:50 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
by Zacks Equity Research
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
by Zacks Equity Research
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.
Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.